Physician profile
Jason Poon
NPI 1417319658
$102,264.71
in general payments reported to CMS, 2019-2025
44 companies · $4,280 in 2025
The $4,280 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $90K · 2021: $947 · 2022: $1,719 · 2023: $1,583 · 2024: $3,405 · 2025: $4,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,086 · Consulting Fee: $3,108 · Education: $74.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,085.93 |
| Consulting Fee | $3,108.00 |
| Education | $74.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $90,024.18 | 2020-2021 | |
| Tg Therapeutics, INC. | $4,490.28 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,562.73 | 2020-2025 | |
| Emd Serono, INC. | $1,231.82 | 2021-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $637.41 | 2022-2025 | |
| Celgene Corporation | $607.18 | 2022-2025 | Zeposia |
| Merz Pharmaceuticals, LLC | $553.43 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $529.13 | 2022-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $373.39 | 2022-2025 | Zeposia |
| Amgen INC. | $220.76 | 2025 | Uplizna |
| Argenx US, INC. | $162.43 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $158.15 | 2022-2025 | Hizentra |
| Genzyme Corporation | $157.91 | 2021-2025 | |
| Janssen Biotech, INC. | $142.98 | 2025 | |
| Acorda Therapeutics, INC | $125.29 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.